Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC Prevention

Tsung-Che Wu; Chia-Chi Lin

doi:10.1158/1940-6207.CAPR-24-0491

Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC Prevention

Cancer Prev Res (Phila). 2025 Jan 6;18(1):7-9. doi: 10.1158/1940-6207.CAPR-24-0491.

Authors

Tsung-Che Wu^{1

2

3}, Chia-Chi Lin^{1

4

5}

Affiliations

¹ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
² Department of Oncology, National Taiwan University Biomedical Park Hospital, Hsinchu, Taiwan.
³ Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
⁴ Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
⁵ Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.

PMID: 39757805
DOI: 10.1158/1940-6207.CAPR-24-0491

Abstract

The study by Downs and colleagues targets patients with non-muscle-invasive bladder cancer (NMIBC) to explore secondary/tertiary cancer prevention strategies. Utilizing a "window-of-opportunity" design, erlotinib was evaluated for its effect on EGFR phosphorylation, although the unconventional dosing regimen failed to demonstrate efficacy. New opportunities in NMIBC prevention include targeting FGFR3 mutations with emerging FGFR inhibitors. A future trial design could focus on clinical outcomes such as tumor response and NMIBC recurrence while also evaluating FGFR3 inhibition in both tumor and adjacent normal bladder epithelia. See related article by Downs et al., p. 31.

MeSH terms

ErbB Receptors* / antagonists & inhibitors
ErbB Receptors* / genetics
Erlotinib Hydrochloride
Humans
Mutation
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / prevention & control
Non-Muscle Invasive Bladder Neoplasms
Protein Kinase Inhibitors* / pharmacology
Protein Kinase Inhibitors* / therapeutic use
Receptor, Fibroblast Growth Factor, Type 3 / antagonists & inhibitors
Receptor, Fibroblast Growth Factor, Type 3 / genetics
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / genetics
Urinary Bladder Neoplasms* / pathology
Urinary Bladder Neoplasms* / prevention & control

Substances

ErbB Receptors
EGFR protein, human
Protein Kinase Inhibitors
Receptor, Fibroblast Growth Factor, Type 3
Erlotinib Hydrochloride
FGFR3 protein, human